Why the Kenya-US Health Data Deal Became a Debate About Leverage

In March this year, clinics across Kenya scrambled to account for an abrupt disruption in donor funding. Supply chains stalled. Programme coordinators fielded questions they could not answer. The moment passed, but it left something behind: a clearer picture of how much of the country’s public health infrastructure still runs on external money, and how little room that leaves when negotiations become complicated.

That context is missing from much of the commentary surrounding the Kenya-US health data deal.

The argument most commonly used to justify broader data-sharing arrangements begins with a fair point. The United States spent billions of dollars building parts of Kenya’s health system. PEPFAR funded laboratories, medicines, digital infrastructure and health workers. Lives were saved. The contribution is real and its scale is not seriously disputed.

The disagreement begins when funding is presented as a basis for broader claims over data.

Supporters of the deal often reach for an investment analogy. Capital goes in, equity comes back. Why should health financing work differently?

The comparison breaks down when examined through the structure of the programme itself. PEPFAR was established as a public health assistance programme, not as an ownership stake in Kenya’s health sector. It created reporting requirements, oversight mechanisms and performance obligations. Those arrangements support accountability. They do not automatically establish ownership rights over the information generated within the system.

That distinction sits at the centre of the current dispute.

A government agency reporting on HIV treatment outcomes is doing something different from a pharmaceutical company seeking information that could support future product development. Anonymised epidemiological research raises different questions from long-term commercial rights or intellectual property claims. These distinctions shape modern data governance frameworks because different forms of access create different obligations, protections and benefits.

The discussion also tends to overlook what donor funding often supports in practice. External financing does not only pay for medicines, laboratory equipment and treatment programmes. In many countries it also supports data capturers, tracing teams, community health workers and the administrative systems that keep patients connected to care. Those investments strengthen the case for programme evaluation and accountability. They do not, on their own, settle questions about ownership, access rights or future use of the resulting data.

Kenya’s own government is approaching a related issue through a similar lens.

Officials are developing a framework to commercialise selected non-personal datasets generated through eCitizen and other public systems. The proposal includes licensing models, pricing structures and defined categories of access. Researchers, businesses and public institutions would not automatically receive identical rights over government-held information. Access would be governed through specific conditions and specific purposes.

The significance of that approach extends beyond the eCitizen platform.

It reflects a broader recognition that ownership, access, licensing and commercial use are not interchangeable concepts. They require separate rules. They create separate rights. They raise separate policy questions.

The legal challenge currently before Kenya’s High Court points in the same direction.

When consumer groups challenged the Kenya-US agreement, the court did not suspend the entire health partnership. It temporarily halted implementation of provisions relating to the transfer and sharing of sensitive health data while the case proceeds. The government’s response was equally revealing. Officials defended the agreement by arguing that Kenyan sovereignty, data ownership and intellectual property remain protected.

Both positions treat data governance as a distinct question rather than a simple extension of funding arrangements.

The court dispute has also exposed another issue that receives less attention. Questions about data are often also questions about jurisdiction. Access rights are one part of the discussion. The legal framework governing that access is another. Which country’s laws apply? Which institutions enforce compliance? Where do citizens seek remedies if protections fail? These questions sit alongside debates about ownership and access, yet they are frequently overlooked when data-sharing arrangements are discussed in broad terms.

The same complexity appears in discussions about pathogen samples, genomic information and medical research. Public-health cooperation may involve sharing data that contributes to future discoveries, diagnostics or treatments. That creates questions about benefit-sharing, intellectual property and future commercial value. Access to information does not automatically answer questions about who benefits from what is eventually developed from it.

That matters because public debate often compresses everything into a single argument. Donor funding, accountability, research access, commercial use, legal jurisdiction, benefit-sharing and ownership are frequently discussed as though they automatically travel together.

They do not.

The dependency question remains separate and far more difficult.

The funding disruption earlier this year made visible what was already structurally true. Governments that rely heavily on external financing have less room to manoeuvre during negotiations. They absorb funding shocks less easily. They operate under greater pressure when partnerships are being renegotiated. Dependence shapes negotiating outcomes. The effect appears regardless of the intentions of either party.

Recent developments elsewhere on the continent underscore the challenge. South Africa finances a far larger share of its HIV response domestically than many African countries, yet it is still preparing for the consequences of a major reduction in PEPFAR support. Health officials have warned about pressure on treatment programmes, outreach systems and support personnel that operate alongside clinical care. The lesson is not that donor funding is undesirable. It is that long-term reliance on external financing creates vulnerabilities even in comparatively stronger systems.

This reality strengthens the case for greater domestic investment in healthcare. It strengthens the case for reducing long-term dependence on external financing. It strengthens the case for building stronger local institutions capable of funding and governing critical public systems.

It does not resolve questions about ownership.

Kenya is entering a period in which data carries increasing economic, scientific and strategic value. Government policy already reflects that shift. The proposed eCitizen marketplace, debates over health data, and wider discussions about digital sovereignty all point to the same development.

Data is no longer viewed solely as an administrative by-product of public services. It is increasingly viewed as a national asset that requires governance frameworks, access rules and clear definitions of rights and responsibilities.

That is the larger issue emerging from the current controversy.

The Kenya-US health data deal has become a proxy for a broader national conversation. The central question is not whether accountability matters. Few people dispute that it does. The question is how access, ownership, licensing, jurisdiction, benefit-sharing and public benefit should be governed once data acquires strategic value.

The court case, the government’s own data policies and the public debate all suggest the same thing.

Kenya is moving into an era where the governance of data will matter as much as the collection of it.

The decisions made now will shape who benefits from that value, who controls access to it, which laws govern its use and how much room the country has to make those choices on its own terms.

Go to TECHTRENDSKE.co.ke for more tech and business news from the African continent and across the world.

Follow us on WhatsApp, Telegram, Twitter, and Facebook, or subscribe to our weekly newsletter to ensure you don’t miss out on any future updates. Send tips to editorial@techtrendsmedia.co.ke